Cancer cell–selective in vivo Treating cancer with light activated, antibody-dye conjugates by Amol Kapoor and Teddy Leithead Makoto Mitsunaga, Mikako Ogawa, Nobuyuki Kosaka, Lauren Rosenblum, Peter L Choyke & Hisataka Kobayashi near infrared photoimmunotherapy targeting specific membrane molecules
Overview Cancer treatments focus on minimal side effects with maximal cancer cell death Photoimmunotherapy (PIT) IR700 + Trastuzumab and Panitumumab. IR700 toxic only when bound Specific antibodies could allow for the treatment of many cancers
Background Photo Dynamic Therapy (PDT) Excited photosensitizers -> Singlet oxygen Singlet oxygen -> cell death Immunotherapy Uses the body's defense mechanism Antibodies
Introduction PIT = PDT + Immunotherapy PDT -> Toxicity Immunotherapy -> Specificity PIT makes a strong therapy because of low healthy cell death
Review PDT PIT Immunotherapy
Results-In Vitro 73%78% 3T3-HER2 cells and A431 HER1 cells Significant cell death from both conjugates Irradiation -> Cell death
Results-In Vitro (Cont.) Tra-IR toxic only when bound Cellular uptake is unnecessary
Results-In Vivo
Results-In Vivo (Cont.) Tumor size Life span Rats w/ treatment Repeated treatment of drug led to tumor free survival at over four months
Discussion IR700 is hydrophilic and has high extinction coefficient More effective than other photosensitizers. mAb-1700 is highly selective Conjugate is non-toxic when unbound from Kobayashi: Mechanism of action and FDA trials
Conclusion/Summary A target specific PIT was developed NIR light irradiation + the conjugate leads to large cancer cell death Highly effective in vitro and in vivo
Future Research For clinical trials, mAb-IR700’s toxicity mechanism must be understood Researchers must confirm a minimal threat to non- cancerous cells Unique mAbs -> PIT applied to multiple cancers for diagnosis and treatment
Why It Matters Completely Revolutionizes Field Potentially makes other drugs obsolete The likelihood of one of us getting cancer is high. Perfected, this offers a way to stop all cancers.